Hong Kong's Codex Genetics has formed a strategic partnership with C2N Diagnostics, a global leader in brain health. This collaboration will introduce the innovative PrecivityAD2™ blood test to healthcare professionals across Hong Kong. The initiative provides a new, accessible tool for the early diagnosis of Alzheimer's disease, addressing a critical healthcare challenge.
A New Frontier in Alzheimer's Diagnostics
The PrecivityAD2™ test is designed for individuals aged 50 and older who show symptoms of cognitive decline. It functions by detecting brain amyloid pathology, a primary hallmark of Alzheimer's disease. This advanced diagnostic tool provides clinicians with vital information to support a comprehensive evaluation.
Utilizing high-resolution mass spectrometry, the test analyzes key blood biomarkers, including the amyloid beta ratio and phosphorylated tau protein levels. A proprietary algorithm then processes these measurements to produce a clear positive or negative result. This indicates the likelihood of amyloid plaque presence in the brain.
Clinically Validated Performance and Accuracy
Clinical validation studies have demonstrated the test's robust performance, with 91% accuracy, 90% sensitivity, and 92% specificity compared to PET imaging. These results meet the stringent criteria set by the 2025 Alzheimer's Association guidelines. This high reliability makes it a trustworthy tool for medical professionals.
A 2024 study in the Journal of the American Medical Association further solidified the test's credibility. The research highlighted its ability to significantly improve diagnostic accuracy in primary care settings where initial evaluations occur. The test achieved over 90% accuracy against established methods like cerebrospinal fluid analysis.
Addressing a Growing Public Health Challenge
This test's introduction is timely for Hong Kong, where an aging population faces a rising incidence of Alzheimer's. Local data shows that about 20% of older adults experience mild neurocognitive impairment, while 7.4% have dementia. These figures underscore the urgent need for more accessible diagnostic solutions.
Dr. Aldrin Yim, Co-Founder of Codex Genetics, stated the collaboration reinforces the company's commitment to precision medicine. He emphasized that the test offers a practical and less invasive alternative to PET scans or lumbar punctures. This enables clinicians to make earlier, more informed decisions in all healthcare settings.
Strategic Partnership for Enhanced Access
Dr. Joel Braunstein, CEO of C2N, expressed confidence in the partnership, citing Codex Genetics' expertise in precision diagnostics. He noted that Codex is an ideal partner to help expand access to this critical Alzheimer's evaluation tool. The collaboration aims to better support clinicians and patients throughout the diagnostic journey.
The PrecivityAD2™ blood test provides a highly accurate and convenient option for evaluating cognitive impairment. Its accessibility is beneficial where PET imaging or cerebrospinal fluid testing may be unavailable or unsuitable for the patient. This partnership directly addresses these limitations by bringing a leading-edge solution to the market.
The alliance between Codex Genetics and C2N Diagnostics represents a significant advancement for Alzheimer's care in Hong Kong. By introducing the accurate and accessible PrecivityAD2™ blood test, the partnership is poised to enhance diagnostic capabilities and improve patient outcomes. This initiative marks a crucial step in addressing the public health challenge posed by neurocognitive disorders.